News
NVNO
4.990
+0.81%
0.040
Weekly Report: what happened at NVNO last week (0506-0510)?
Weekly Report · 5d ago
enVVeno Medical Corp reports results for the quarter ended in March - Earnings Summary
EnVVeno Medical Corp reports results for the quarter ended in March. The company reported a quarterly adjusted loss of 31 cents per share; analysts expected a loss of 40 cents. The average analyst rating on the shares is "strong buy" for the company. Shares have fallen 8.6% this quarter and 3.3% so far this year.
Reuters · 05/11 00:03
enVVeno Medical reports Q1 results
EnVVeno Medical Corporation (NVNO) reports Q1 net loss of $5.0 million. Cash burn for the quarter was $3.5 million, better than the Company's projected cash burn rate of $4-5 million per quarter.
Seeking Alpha · 05/09 16:38
Financial Report Articles: EnVVeno Medical Corporation - Form 10-Q for the Quarterly Period Ended March 31, 2024
Press release · 05/09 07:54
NVNO Stock Earnings: enVVeno Medical Beats EPS for Q1 2024
EnVVeno Medical reported earnings per share of -31 cents for the first quarter of 2024. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -40 cents. EnVVoena Medical is a medical company.
Investorplace · 05/09 03:54
enVVeno Medical Q1 EPS $(0.31) Beats $(0.40) Estimate
Benzinga · 05/08 22:13
Weekly Report: what happened at NVNO last week (0429-0503)?
Weekly Report · 05/06 10:56
enVVeno Medical Corp <NVNO.OQ> expected to post a loss of 40 cents a share - Earnings Preview
EnVVeno Medical Corp expected to post a loss of 40 cents a share. The one available analyst rating on the shares is "strong buy" Wall Street's median 12-month price target for the company is $20.40.
Reuters · 05/04 02:02
Weekly Report: what happened at NVNO last week (0422-0426)?
Weekly Report · 04/29 11:01
enVVeno Medical’s VenoValve Trial Shows Promising Results
TipRanks · 04/24 10:32
Weekly Report: what happened at NVNO last week (0415-0419)?
Weekly Report · 04/22 10:53
Weekly Report: what happened at NVNO last week (0408-0412)?
Weekly Report · 04/15 10:46
Weekly Report: what happened at NVNO last week (0401-0405)?
Weekly Report · 04/08 10:50
Weekly Report: what happened at NVNO last week (0325-0329)?
Weekly Report · 04/01 10:48
Weekly Report: what happened at NVNO last week (0318-0322)?
Weekly Report · 03/25 10:50
Weekly Report: what happened at NVNO last week (0311-0315)?
Weekly Report · 03/18 10:49
Weekly Report: what happened at NVNO last week (0304-0308)?
Weekly Report · 03/11 10:46
enVVeno: The Road To Approval Seems Open From Here On
EnVVeno Medical Corporation has released positive topline data from its pivotal trial for the VenoValve. The path to file for approval in Q4 2024 seems open for the company. The company's treatment targets a significant market of 2.5 million patients in the US alone. The Veno valve has potential pricing between $20,000 and $25,000 per device.
Seeking Alpha · 03/06 22:59
BeyondSpring, enVVeno Medical, Aptorum Group among healthcare movers
Healthcare On the Move BeyondSpring, enVVeno Medical, Aptorum Group among healthcare movers. S&P 500 Health Care Sector +0.6% to 1697.2. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 03/06 15:00
EnVVeno Medical’s VenoValve Trial Shows Promising Results
TipRanks · 03/06 13:52
More
Webull provides a variety of real-time NVNO stock news. You can receive the latest news about Envveno Medical Corporation through multiple platforms. This information may help you make smarter investment decisions.
About NVNO
enVVeno Medical Corporation is a late-stage clinical med-tech company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (CVI) of the deep venous system of the leg. The Company's lead product, VenoValve, which is a porcine based replacement venous valve developed to surgically implanted in the deep venous system of the leg to treat severe CVI. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a five-to-six-inch incision in the upper thigh. The VenoValve is being evaluated in the surgical anti-reflux venous valve endoprosthesis (SAVVE) United States clinical trial. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter based replacement venous valve.